Nucleoside compounds for treating viral infections
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
-
Citations
24 Claims
- 1. A compound of Formula I:
- 3. A compound of Formula II:
- 5. A compound of Formula III:
- 7. A compound of Formula IV:
- 9. A compound of Formula V:
- 11. A compound of formula VI:
- 13. A compound according to Formula VII:
- 15. A compound of Formula VIII:
-
17. A compound of Formula IX:
-
18. A compound selected from the group consisting of:
-
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(diisopropoxymethyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(formyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(carbaldehyde oxime)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(boronic acid)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(diethoxymethyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(formyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(carbaldehyde oxime)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(boronic acid)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(diethoxymethyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(formyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(formyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(boronic acid)-pyrrolo [2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(diethoxymethyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(formyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(formyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(boronic acid)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(diethoxymethyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-methyl-β
-D-ribofuranosyl)-4-amino-5-(hydrazono)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(hydrazono)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(hydrazono)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(hydrazono)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-monophospho-β
-D-ribofuranosyl)-4-amino-5-(diisopropoxymethyl)-pyrrolo[2,3-d]pyrimidine;
7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(diisopropoxymethyl)-pyrrolo[2,3-d]pyrimidine; and
7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(diisopropoxymethyl)-pyrrolo[2,3-d]pyrimidine;
or pharmaceutically acceptable salts or partial salts thereof.
-
Specification